By Dinesh C Sharma
Published on August 17, 2017
Thousands of infants die due to infections in the first few weeks of their life. A bulk of these deaths can be prevented with an inexpensive probiotic-based preventive therapy developed by a group of Indian and American scientists.
The therapy has been tested in over 4,500 infants from 149 villages in Odisha. Results of this trial, published this week in international journal Nature, show that the probiotic when given orally for one week after birth can reduce sepsis and death by 40 percent. In addition, it also drastically reduces respiratory tract infections. This is the largest ever clinical study of probiotics conducted among new born babies.
Sepsis is a severe complication of bacterial infection that results in around one million infant deaths globally every year.
The preventive therapy is called synbiotic treatment - a combination of probiotic bacteria and a prebiotic nutrient to support the probiotic strain. While probiotics are live micro-organisms that can provide a health ben¬efit, prebiotics are molecules such as certain carbohydrates in human milk or those derived from plants.
In the Odisha study, the synbiotic prepara¬tion was given daily for one week to full-term born babies when they were two to four days old. The oral preparation contained Lactobacillus plantarum, which had earlier been found to have shown good gut-colonizing properties in newborns, along with fructooligosaccharide, a plant-derived prebiotic.
The therapy was given in addition to breast milk which is known to contain prebiotics as well as other molecules that provide immunity to babies. Only mothers who had started breast feeding their children in their first 24 hours were included in the study.
Follow-up showed that the therapy reduced the risk of sepsis or death by 40 percent. Substan¬tial reductions were seen in all three subtypes of sepsis assessed, and reductions were also observed in diarrhoea and umbilical-stump infection in infants who had not been classified as having sepsis.
“This will reduce the nagging high neonatal mortality and infant mortality in developing countries. More importantly, reduction of such infections during infancy can prevent ‘stunting’ with even more grievous consequences such as reduced cognition and chances of chronic diseases such as hypertension and diabetes in early adulthood,” Pinaki Panigrahi of University of Nebraska Medical Center, who led the research team told India Science Wire. He said it is an affordable intervention as one-week therapy costs just one dollar.
“The trial provides evidence for the effectiveness of a global health interven¬tion that could be used to complement exist¬ing strategies for giving every newborn the best chance to survive and thrive,” pointed out Daniel J. Tancredi of University of California, in a commentary published in the same issue of Nature.
The research team included Pinaki Panigrahi, Sailajanandan Parida, Nimai C. Nanda, Radhanath Satpathy, Lingaraj Pradhan, Dinesh S. Chandel, Lorena Baccaglini, Arjit Mohapatra, Subhranshu S. Mohapatra, Pravas R. Misra, Rama Chaudhry, Hegang H. Chen, Judith A. Johnson, J. Glenn Morris Jr, Nigel Paneth and Ira H. Gewolb.